Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of September 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory filings rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary activity reported is the submission of an application for the quotation of securities (ATH).
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference into Registration Statements on Form S-8 and Form F-3.
Exhibits: Exhibit 99.1 contains the "Application for quotation of securities - ATH".
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 6-K.
Investor Verification Checklist
- Verify the status of the "Application for quotation of securities - ATH" referenced in Exhibit 99.1.
- Review the incorporated Registration Statements (Form S-8 and Form F-3) for detailed capital structure and offering terms.
- Confirm the company's continued classification as a development stage enterprise and its cash runway.
- Check for subsequent filings regarding the outcome of the securities quotation application.